JP7125725B2 - ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用 - Google Patents

ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用 Download PDF

Info

Publication number
JP7125725B2
JP7125725B2 JP2020564078A JP2020564078A JP7125725B2 JP 7125725 B2 JP7125725 B2 JP 7125725B2 JP 2020564078 A JP2020564078 A JP 2020564078A JP 2020564078 A JP2020564078 A JP 2020564078A JP 7125725 B2 JP7125725 B2 JP 7125725B2
Authority
JP
Japan
Prior art keywords
phenylalanine
dihydroxy
magnetic resonance
poly
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518479A (ja
JP2021518479A5 (enExample
Inventor
継紅 孫
君 凌
佳宇 岑
岳棟 苗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Publication of JP2021518479A publication Critical patent/JP2021518479A/ja
Publication of JP2021518479A5 publication Critical patent/JP2021518479A5/ja
Application granted granted Critical
Publication of JP7125725B2 publication Critical patent/JP7125725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Polyamides (AREA)
JP2020564078A 2018-05-16 2019-05-13 ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用 Active JP7125725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810468018.2A CN110496231B (zh) 2018-05-16 2018-05-16 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用
CN201810468018.2 2018-05-16
PCT/CN2019/086586 WO2019218960A1 (zh) 2018-05-16 2019-05-13 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用

Publications (3)

Publication Number Publication Date
JP2021518479A JP2021518479A (ja) 2021-08-02
JP2021518479A5 JP2021518479A5 (enExample) 2022-01-06
JP7125725B2 true JP7125725B2 (ja) 2022-08-25

Family

ID=68539457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564078A Active JP7125725B2 (ja) 2018-05-16 2019-05-13 ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用

Country Status (4)

Country Link
US (1) US20210052749A1 (enExample)
JP (1) JP7125725B2 (enExample)
CN (1) CN110496231B (enExample)
WO (1) WO2019218960A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306650B (zh) * 2022-01-21 2022-12-06 南方医科大学 一种磁性四氧化三铁纳米粒及其制备方法和应用
CN118987284A (zh) * 2024-10-25 2024-11-22 杭州奥赛瑞生物医药科技有限责任公司 一种聚合物纳米胶束及其在增强ct成像中的应用
CN118987283A (zh) * 2024-10-25 2024-11-22 杭州奥赛瑞生物医药科技有限责任公司 基于聚氨基酸纳米胶束的多模态对比剂及制备方法和应用
CN119033973A (zh) * 2024-10-30 2024-11-29 杭州奥赛瑞生物医药科技有限责任公司 一种透明质酸修饰的铁基聚多巴氨基酸纳米探针及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514301A (ja) 2011-06-22 2014-06-19 ハンファ ケミカル コーポレーション 酸化鉄ナノ粒子に基づくリンパ系造影用ｍｒｉ造影剤およびこれを用いてリンパ節を造影する方法
JP2016069358A (ja) 2014-09-26 2016-05-09 ソウル大学校産学協力団 癌細胞の造影用ｍｒｉ造影剤組成物
CN106916301A (zh) 2017-04-14 2017-07-04 四川大学 高载铁量聚多巴胺纳米粒子的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161020A1 (en) * 2008-09-09 2010-03-10 Koninklijke Philips Electronics N.V. Chelating amphiphilic polymers
CN104140546B (zh) * 2014-06-27 2017-02-15 江南大学 一种类碳纳米管状可降解聚合物的制备方法
CN105524271B (zh) * 2014-10-24 2018-07-03 江苏师范大学 胆酸修饰的聚氨基酸嵌段共聚物的合成及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514301A (ja) 2011-06-22 2014-06-19 ハンファ ケミカル コーポレーション 酸化鉄ナノ粒子に基づくリンパ系造影用ｍｒｉ造影剤およびこれを用いてリンパ節を造影する方法
JP2016069358A (ja) 2014-09-26 2016-05-09 ソウル大学校産学協力団 癌細胞の造影用ｍｒｉ造影剤組成物
CN106916301A (zh) 2017-04-14 2017-07-04 四川大学 高载铁量聚多巴胺纳米粒子的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gyu Ha Hwang et al.，pH-Responsive robust polymer micelles with metal-ligand coordinated core cross-links，Chem. Commun.，2014年03月18日，Volume 50, Issue 33，4351-4353
Yiwen Li et al.，Polycatechol Nanoparticle MRI Contrast Agents，Small，2016年02月03日，vol. 12, issue 5，p. 668-677

Also Published As

Publication number Publication date
CN110496231A (zh) 2019-11-26
US20210052749A1 (en) 2021-02-25
JP2021518479A (ja) 2021-08-02
WO2019218960A1 (zh) 2019-11-21
CN110496231B (zh) 2020-09-18

Similar Documents

Publication Publication Date Title
Bae et al. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T 1-and T 2-weighted magnetic resonance imaging
Li et al. Macromolecular ligands for gadolinium MRI contrast agents
Li et al. Magnetite-loaded fluorine-containing polymeric micelles for magnetic resonance imaging and drug delivery
JP7125725B2 (ja) ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用
Peng et al. Targeted tumor CT imaging using folic acid-modified PEGylated dendrimer-entrapped gold nanoparticles
Yan et al. Recent advances in multifunctional magnetic nanoparticles and applications to biomedical diagnosis and treatment
Li et al. Folate-bovine serum albumin functionalized polymeric micelles loaded with superparamagnetic iron oxide nanoparticles for tumor targeting and magnetic resonance imaging
An et al. Paramagnetic hollow silica nanospheres for in vivo targeted ultrasound and magnetic resonance imaging
Rowe et al. Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers
Zhu et al. Magnetic, fluorescent, and thermo-responsive Fe3O4/rare earth incorporated poly (St-NIPAM) core–shell colloidal nanoparticles in multimodal optical/magnetic resonance imaging probes
Peng et al. Facile formation of dendrimer-stabilized gold nanoparticles modified with diatrizoic acid for enhanced computed tomography imaging applications
US20090180966A1 (en) Cancer cell diagnosis by targeting delivery of nanodevices
EP0177545A1 (en) USE OF FERROMAGNETIC PARTICLES IN CONTRAST AGENTS FOR IMAGE FORMATION BY NUCLEAR MAGNETIC RESONANCE (NMR), AND CONTRAST AGENTS.
EP2922577B1 (en) Superparamagnetic iron oxide nanoparticles with ultra-thin polymer layers
Liu et al. Mixed polymeric micelles as multifunctional scaffold for combined magnetic resonance imaging contrast enhancement and targeted chemotherapeutic drug delivery
CN113583178B (zh) 一种支化含糖聚合物基纳米粒子及其的制备方法和用途
Galperin et al. Synthesis and characterization of radiopaque magnetic core‐shell nanoparticles for X‐ray imaging applications
Hosseini et al. Synthesis of pseudopolyrotaxanes-coated Superparamagnetic Iron Oxide Nanoparticles as new MRI contrast agent
Fu et al. Gadolinium (iii) complex-backboned branched polymers as imaging probes for contrast-enhanced magnetic resonance angiography
Wang et al. Trifunctional polymeric nanocomposites incorporated with Fe3O4/iodine-containing rare earth complex for computed X-ray tomography, magnetic resonance, and optical imaging
TW588018B (en) Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof
Jackson et al. Synthesis and in vivo magnetic resonance imaging evaluation of biocompatible branched copolymer nanocontrast agents
Zhou et al. Nanocomposites of ionic copolymer integrating Gd-containing polyoxometalate as a multiple platform for enhanced MRI and pH-response chemotherapy
Chen et al. Amphiphilic core–shell nanocomposite particles for enhanced magnetic resonance imaging
EP2647391A1 (en) Mri contrast agent containing composite particles

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201214

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201214

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210407

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210705

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220803

R150 Certificate of patent or registration of utility model

Ref document number: 7125725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250